uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Study acronym: uTRACT
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Apr 2026 → Oct 2027
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from UroGen Pharma Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 2026 to Oct 2027 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 400 → 450 participants
    • Study completion pushed from Jan 2028 to Oct 2030
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: 3 to 5
    • Study description expanded, about 9 words
    • Study sites revised (22)
  2. Primary completion date: Apr 2025 to Apr 2026
    • Primary endpoint revised
    • Study sites: 1 to 22
    • Eligibility criteria expanded, about 72 words
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jul 2023 to Nov 17, 2023
    • Study sites: 0 to 1
    • Primary completion date: Oct 2025 to Apr 2025
    • Study completion date: Jul 2028 to Jan 2028
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Trial Details
NCT Number NCT05874921
Lead Sponsor UroGen Pharma Ltd.
Conditions
(from sponsor)		 Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Related terms Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov